Life Insurance With Hypermobility, EDS or Marfan in Canada

Simplified coverage gets treated as the consolation prize, the thing you settle for after a carrier turns you down. With connective tissue disorders it is frequently worth looking at first, and sometimes it is the route that produces an answer in days rather than months.

The reason comes down to how the two application types are built. A fully underwritten application usually contains a broad catch-all question that pulls in symptoms, investigations and anything still unresolved. A simplified application usually asks a shorter, more defined set of medical questions and does not normally require a medical exam. It may still ask about symptoms, pending investigations, recent treatment and other eligibility factors, depending on the insurer and the product.

That difference decides more of these cases than people expect. What follows covers both routes for each condition, what each one costs, and how to get a real indication from an insurer before anything goes on your permanent record.

Why Connective Tissue Disorders Are Hard to Price (and What Brokers Do About It)

When a condition is rare, or one I have not come across before, that is definitely a case where I reach out to carriers and run a preliminary assessment. I think it is imperative to know without guessing.

Here is the part nobody tells you. Ehlers-Danlos, Marfan and osteogenesis imperfecta barely appear in the underwriting guides Canadian brokers are given. Not buried in a footnote. Not there. Lupus and scleroderma have entries at most carriers. The heritable conditions largely do not.

What a preliminary assessment actually is

It is a real file, sent to a real underwriter, with your name taken off it. The only thing I leave out is the client’s actual identifying information. Beyond that, anything and everything relevant to an underwriting decision goes in. The more information provided, the more likely the outcome matches what the preliminary assessment delivers.

How long it takes

Sometimes a day or two. More often one to two weeks. Certain times of year run slower, around the holidays and through the summer especially. I prepare clients for up to ten business days and treat anything faster as a bonus.

I am not going to pretend every answer comes back as a number. Sometimes it does. Sometimes it comes back as a range, and sometimes it comes back as send it in and we will look properly. All three are worth having, because all three are better than submitting blind and finding out afterward. A preliminary assessment is an indication rather than an offer, and the formal application still governs the outcome.

Underwriters are pricing uncertainty, not the label. A documented, stable file with current imaging and a specialist who sees you on a predictable schedule is something an insurer can put a number against. A file with a diagnosis and gaps in it is something they are more likely to rate heavily or pause on. Most of what follows is about closing those gaps before anyone sees your file.

The Two Types of Connective Tissue Disorder Insurers Treat Completely Differently

Canadian insurers do not underwrite connective tissue disorders as one category. They split them into heritable conditions and autoimmune conditions, and the two are assessed on almost entirely different questions.

This matters more than it sounds. The stability question that decides an autoimmune file is close to meaningless on a heritable one, and applying the wrong logic to your own situation is how people talk themselves out of coverage they could have had.

Why the guides themselves are split this way

Read the Canadian underwriting guides side by side and the divide is obvious. Canada Life groups the autoimmune conditions under a single “collagen diseases” heading covering scleroderma, morphea, lupus, dermatomyositis, polyarteritis nodosum, temporal arteritis and mixed connective tissue disease. Sun Life’s 2026 guide carries a detailed lupus entry. Industrial Alliance grades scleroderma by whether it is localized or generalized.

Now look for Ehlers-Danlos or Marfan in those same guides. They are largely absent. Foresters lists Marfan, but in a genetic and family history table rather than among the medical impairments. That is not carriers refusing to cover these conditions. It is a gap in published guidance, and it is why the heritable half of this page leans on structural markers like aortic measurements, which carriers do publish on, rather than on a condition name they do not address directly.

Ehlers-Danlos and Hypermobility Life Insurance: Why the Subtype Matters Most

Many people with hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder, with no vascular or organ involvement, are able to get life insurance in Canada, and some no-medical applications do not name connective tissue disease in their health questions at all. Vascular EDS is assessed very differently, and the gap between subtypes is wider here than for most conditions I place.

The complication is that Canadian carriers publish almost nothing on it. Across the twelve Canadian underwriting guides reviewed for this page, Ehlers-Danlos does not appear as a medical impairment in any of them. Munich Re Canada has published an underwriting case clinic on the Ehlers-Danlos syndromes, so a considered view exists on the reinsurance side. It has not filtered down into the guides brokers work from day to day.

How the subtypes are weighed

When you have symptoms but no formal diagnosis

This is a very important one. Where someone has not been formally diagnosed but they might have symptoms, simplified can be a much stronger option than fully underwritten, which may have a catch-all question that includes the symptoms.

The advantage of a simplified policy is the more direct questions. Where you are able to answer them accurately, an offer can follow quickly, subject to the insurer’s eligibility rules and approval. With fully underwritten, under a catch-all, it may require you to disclose the symptoms and a potential underlying condition.

Which is the opposite of what many people assume. They think the diagnosis is what hurts them, so they wait for one. In practice a fully underwritten application can turn an unresolved investigation into a postponement, while a no-medical application asking about a defined list of named conditions may not reach it. iA Access Life, the simplified line, works through four steps of health questions covering a defined set of conditions, and connective tissue disease is not named among them.

Because so little is published on these subtypes, an anonymous preliminary assessment does more work here than on most other conditions. Outcomes depend on the complete application and remain subject to insurer approval, but it is usually possible to get a reasonable indication of where you stand before anything is formally submitted.

Marfan Syndrome Life Insurance in Canada: Your Aortic Root Measurement Carries the Most Weight

For Marfan syndrome and related aortic conditions, a recent aortic root measurement is usually one of the most important parts of the file. A normal and stable measurement may keep traditional coverage in consideration. Dilation can materially narrow the market available to you.

Marfan itself is not written up as a medical impairment in the Canadian carrier guides reviewed for this page. What the guides do cover in detail is the aorta. So that is where the useful information sits.

Sun Life field underwriting guide

Bicuspid aortic valve entry. Applies only where diagnosis is confirmed by echocardiogram.

Illustrative only, drawn from published guidance available at the time of writing, and subject to underwriting and change.

What the guides do say about Marfan directly

One carrier addresses it by name. Foresters lists Marfan syndrome at +50 to decline for life insurance and decline for critical illness. It sits in their genetic and family history section rather than among medical impairments, which tells you something about how the industry currently files this condition.

That +50 matters. It indicates a well-managed Marfan case is not automatically a decline in this market, whatever you may read on American and British sites. Where any individual file lands depends on the cardiac picture and the full application.

Related aortic findings and how they are treated

Aortic aneurysm. Canada Life’s impairment guidelines are direct: where an aneurysm is present there is always a risk of rupture and insurance cannot be considered. Where one is associated with cerebrovascular or coronary artery disease, the same applies. An attending physician’s statement, meaning a report from your own doctor or specialist, is often required.

Aortic valve stenosis or regurgitation. Canada Life describes outcomes ranging from standard to decline depending on age, severity and complications, typically requiring a physician’s report plus an ECG and chest x-ray. Sun Life’s guidance is tighter, indicating a decline unless the stenosis is mild only, asymptomatic, and the applicant is over 65 with normal ejection fraction.

Coarctation of the aorta. Worth flagging because the outcome is more encouraging than many people expect. Canada Life indicates that without surgery most cases cannot be considered, but that several years after surgery most cases are insurable at standard rates. Repaired, stable and well documented can genuinely mean standard.

The critical illness gap worth planning around

Look again at the readout above. On a normal aortic root under age 50, life insurance is indicated at a rating while critical illness is a decline. Two products, one file, opposite answers.

That is worth planning around rather than discovering later, particularly since aortic surgery is itself a covered condition under many Canadian critical illness contracts. If both products matter to you, the order in which you apply is a real decision. Our overview of whether critical illness insurance is right for you covers how the two fit together.

Systemic Lupus: Why the Same File Gets Different Answers From Different Insurers

Not every company asks the questions the same way, and the same knockout question at one company may not be the same at another. With systemic lupus that difference often shapes the outcome more than the diagnosis does. One major Canadian insurer can consider standard rates on a quiet file. Another may decline on the diagnosis alone.

I place a lot of autoimmune files and this is among the widest spreads I see on any single condition. Same person, same bloodwork, same specialist letter. Very different answers. This section is a summary within a broader hub, and our dedicated guide to life insurance with lupus in Canada goes considerably deeper on application questions, disclosure and options.

Fully underwritten positions on systemic lupus

Based on published carrier guidance available at the time of writing. Illustrative only. Positions vary by insurer, change over time, and any outcome depends on the complete application and insurer approval.

Where lupus is named on a no-medical application, and where it is not

Simplified applications ask about a defined set of conditions. Whether lupus is named varies by carrier, and it can be the difference between an offer in days and no offer at all. Question sets differ between insurers and are revised over time, so current wording should always be confirmed before applying.

Critical illness is a separate conversation

Critical illness generally runs tighter than life on this condition. Sun Life indicates it is unlikely to be considered within four years of diagnosis, or where there is current steroid or immunosuppressant use. Industrial Alliance’s best case is recovery with treatment ceased for more than five years, otherwise a decline.

Where lupus is affecting your ability to work rather than your mortality risk, income protection is often the more relevant product, and it is underwritten on different criteria. Our guide to disability insurance with a pre-existing condition covers how that assessment differs.

One last thing worth flagging. Lupus often does not arrive alone, and thyroid autoimmunity is a common companion. That is generally a smaller factor than the lupus itself, and our guide to life insurance with Hashimoto’s disease covers how it is treated. Every outcome above depends on the complete application and remains subject to insurer approval.

Life Insurance With Scleroderma, CREST or Osteogenesis Imperfecta (Two Are in the Guides, One Isn’t)

With scleroderma, the diagnosis alone tends to put a rating on the file before anyone looks at how you are actually doing. Across the fully underwritten carrier guidance I have reviewed, the most favourable starting position for a localized case generally sits around a 50% rating. Which, as starting positions go, is not the end of the world.

Other carriers may rate more heavily, postpone, or decline, and where the disease is systemic that becomes considerably more likely. What happens next depends almost entirely on one distinction, and it is a distinction a lot of applications never give people the chance to make.

Localized, generalized, or organs involved

Canadian guides grade this by how far the disease has travelled. The thicker the rule below, the harder the file.

Drawn from published carrier guidance available at the time of writing. Illustrative only, subject to underwriting and change.

What a real file looks like

A woman in her late thirties, localized scleroderma diagnosed several years earlier, no symptoms, on a low-dose immunosuppressant purely for monitoring. Nothing systemic. Also mildly hypothyroid, which sits under the same broad umbrella and is covered further in our guide to thyroid autoimmunity and life insurance.

Most providers out there will decline it if it is systemic. Because hers is not systemic and it is localized, we applied at the most favourable providers. Industrial Alliance carries the strongest wording I have seen for localized cases, indicating a rating band that starts around 50 and runs to roughly 125 where the disease is confined. Those figures are underwriting-guide ranges rather than a rate card, and any offer depends on the full file. Still, it is a workable outcome on a condition people are often told is uninsurable.

The application asked for a report from her own doctor, with a nurse visit for fluids and vitals as a likely add-on. Then it stalled, and not for any reason connected to the scleroderma. There is a lesson in how that happened, covered in timing and postponement.

The one place where no-medical coverage does not always rescue you

Simplified is often the stronger route on these conditions. Here it frequently is not, and the reason is worth understanding, because it is not the scleroderma.

CREST syndrome

Assessed more cautiously than localized disease and generally grouped with progressive systemic sclerosis. Industrial Alliance’s published position is a decline for both life and critical illness. Foresters assesses it alongside scleroderma on type, duration, severity and function. Where the fully underwritten market is closed to a file, the practical route is a no-medical policy whose question set does not reach the condition, or guaranteed acceptance where it does.

Osteogenesis imperfecta, and the honest answer

Twelve Canadian underwriting guides reviewed for this page. Osteogenesis imperfecta does not appear in any of them, in any form.

So nobody can tell you from a published document what a Canadian carrier will do with brittle bone disease, and any page that quotes you a rating for it is guessing. What an underwriter is likely to look at is fracture pattern and frequency, severity type, surgical hardware, mobility, and whether there is any respiratory or cardiac involvement. Bone fragility as an underwriting factor is discussed in our guide to life insurance with osteoporosis, though the mechanisms are different.

This is precisely the situation where an anonymous preliminary assessment earns its keep. It is also worth knowing that inherited conditions absent from the guides do get placed in this market. Our guides to life insurance with hemophilia and life insurance with Turner syndrome both cover conditions with the same problem, and both have workable routes.

Sjogren’s, Mixed Connective Tissue Disease and the Conditions Nobody Writes Guidelines For

Canadian insurers assess the less common connective tissue conditions under the same framework they apply to lupus: which organs are involved, how long the disease has been quiet, and what medication is keeping it there. The condition name matters far less than those three answers.

Canada Life groups most of them under a single heading in its impairment guidelines, listed below with what that grouping actually means for an application.

Named in the Canadian guides

Grouped as collagen diseases. Insurability turns on diagnosis, time in remission and internal organ involvement.

The conditions that show up on the same file

Autoimmune conditions cluster. Underwriters know this and will ask, so it is better to present the full picture than to have it emerge piece by piece. Several of these are assessed far more leniently than people expect on their own.

If your condition is not named anywhere on this page, that does not mean there is no route to coverage. It usually means no carrier has published a position on it, which is a very different problem and a solvable one. Outcomes in every case depend on the complete application and remain subject to insurer approval.

Simplified or Fully Underwritten: Which Application Should You Actually Complete?

Simplified policies often can be a perfect fit in a situation like this. You answer a certain set of questions, and if you are able to answer no, you can often get cost effective coverage quite quickly, subject to the insurer’s eligibility rules and approval.

That runs against the usual advice, which treats no-medical coverage as the thing you fall back on. On connective tissue disorders specifically, I think that advice is backwards often enough to be worth saying plainly.

The three routes, side by side

Coverage limits, question sets and waiting periods vary by carrier and product tier and change over time. Confirm current terms before applying. The difference between the middle and bottom routes is covered further in simplified versus guaranteed issue life insurance.

What a simplified application asks about

This is where the assumption breaks. iA Access Life, one of the simplified lines available in Canada, works through four steps of health questions. Where every question can be answered no, the top tier, Immediate Plus, provides full coverage from the start with no waiting period, subject to eligibility and approval.

Where fully underwritten is still the right call

Three situations, mainly. When you need more coverage than a simplified cap allows, particularly on a mortgage or income replacement need where term coverage has to match a real liability. When your condition is well documented and quiet, in which case a rated offer will often price better than the simplified alternative. And when a named condition or a medication question blocks the simplified route anyway, which can happen with systemic lupus at several carriers and with steroid use at others.

If you have already been turned down somewhere, that changes the sequencing rather than the options. Our guide on what to do after a life insurance decline covers the order to work in, and whether no-medical coverage is right for you covers the trade-offs in more detail.

Why this is a broker question rather than a website question

Not every policy and not every company asks questions the same way. The same knockout question at one company may not be the same at another company. That is the greatest advantage of working with a broker who understands the broad market.

On these conditions the spread is unusually wide. One carrier names your condition and stops. Another does not mention it. A third does not ask about the condition but asks about the medication you take for it. Going direct to a single insurer means finding out which of those you landed on only after they have your application.

How These Files Get Routed Before Anyone Applies

The first decision on a connective tissue file is not which insurer to apply to. It is whether to apply at all yet, or to find out anonymously first. That call usually comes down to how much of your file is settled and how much is still open.

Below is the way I actually work through it. Not a formula, and every file has something in it that moves the answer, but this is the shape of the thinking.

Illustrative routing only. Every file is assessed individually and any outcome depends on the complete application, current carrier rules and insurer approval.

If you can see your own situation in that table, that is the conversation to have. It takes one call, nothing is submitted anywhere, and you come out of it knowing which route makes sense before anything goes on the record.

Get in touch or call 1-877-654-6119.

What Life Insurance Costs With a Connective Tissue Disorder

On the profiles shown below, skipping the medical exam through a no-medical policy costs roughly two to three times a standard fully underwritten premium, and that gap narrows with age. At 35 the difference is closer to triple. At 55 it is closer to double.

Most pages on this topic will not give you a number at all, because a rated premium depends on an underwriting outcome nobody can predict from a web page. The no-medical premium is different. It depends largely on whether you can answer the questions, which you can look into before you apply. So that is the number worth publishing.

Sample premiums are for illustration only. They assume non-smoker status, the sex shown, $500,000 of 20 year term coverage, no additional health concerns, and eligibility for the underwriting class shown. Fully underwritten figures are best-rate standard class. No-medical figures are the top tier of one simplified line. Final premiums depend on age, sex, coverage amount, term length, health history, product eligibility, current carrier rates and insurer approval. Based on current carrier rates and subject to change.

Reading that table properly

The left-hand columns are what a healthy applicant pays. If your connective tissue disorder results in a rating, your fully underwritten premium sits somewhere above that figure, and no honest page can tell you exactly where. The published ratings elsewhere on this page give you the shape of it: standard to 200% indicated on quiet systemic lupus at one carrier, +50% to +300% at another, a minimum 175% indicated on a normal aortic root under 50.

Which means the more useful comparison is not standard against no-medical. It is your rated offer against no-medical. At 45 or 55, once a rating is applied, those two numbers can land close enough together that the deciding factor becomes how long you are willing to wait.

What actually moves your premium

Age moves it more than the diagnosis does, on these profiles at least. Look at the standard column: a male applicant is shown at $30.15 at 35 and $208.80 at 55 for identical coverage, before any health consideration enters the picture. Close to seven times, purely for waiting twenty years.

Smoking status moves it hard as well. Every figure above is non-smoker. Smoker rates run materially higher across every product and every age band, and there is no version of this condition where nicotine helps the file.

Coverage amount and term length are the levers you control. A shorter term or a lower face amount brings the premium down, and layering a smaller permanent policy underneath term coverage is a common structure where budget is tight. Our guide to the factors that shape a term life premium covers how those pieces interact.

Critical illness and disability pricing

Both are underwritten separately and priced separately, and both generally run tighter than life insurance on these conditions. Critical illness in particular carries declines in situations where life coverage is indicated at a rating, as the aortic root guidance on this page shows. Where income protection matters more to you than a death benefit, that assessment turns on function and occupation rather than mortality. Our guides to critical illness coverage in Canada and disability insurance cover how each is priced.

Why Applications Get Postponed (and Why That Is Not a Decline)

Any life insurance company will typically postpone making a decision until all recommended medical follow-ups are completed. That is among the most common reasons a connective tissue file stalls, and often the outstanding test has nothing to do with the connective tissue disorder itself.

People hear “postponed” and take it as a soft no. It is not. The two words get used interchangeably and they mean different things.

What actually triggers a postponement

Four things account for most of them:

• An incomplete recommended follow-up. Anything your doctor advised that has not been done yet. A scan, a repeat blood panel, a specialist review. This is the big one, and it is where most people get caught.
• An investigation still open. Symptoms under review with no conclusion reached. An underwriter cannot easily price an unknown, so they tend to wait for it to become known.
• Recent surgery or a hospital visit. Most carriers want a recovery milestone and a clearance note before they will look at the file properly.
• A medication change still settling. A new immunosuppressant or a steroid taper underway generally needs a few months of documented response before the picture reads as stable.

How long things take

When to apply now and when to wait

Apply now if your specialist visits are current, your imaging is recent, your medication has been steady for a while, and there is nothing your doctor has recommended that you have not done. Autoimmune conditions in particular tend to reward a documented quiet stretch, so if you are in one, that is the window.

Clear the item first if there is an outstanding scan, an open investigation, a recent operation, or a medication change in the last few months. Applying into any of those often produces a postponement rather than a decision, and you have spent weeks to learn something you already knew.

Most of what causes a postponement is visible before you apply, which is the argument for assembling the file properly first. What that looks like in practice is covered next.

What to Send With Your Application

Anything and everything relevant to an underwriting decision should go in. The more information that can be provided, the more likely the outcome is going to match what the preliminary assessment delivers.

That holds for the formal application too. On these conditions the file that arrives complete gets read very differently from the file the underwriter has to chase. Gaps do not read as neutral. They read as unknowns, and unknowns get priced.

What you send, and what it is read for

Expect a report from your own doctor to be requested on almost any fully underwritten application involving one of these conditions. Depending on age and coverage amount, a nurse visit for fluids and vitals may be added. Neither is a bad sign. It is the normal shape of the process.

Additions worth including for specific conditions

Two things that quietly damage a file

Answers that do not match the records. Not usually dishonesty. Usually a date remembered wrong, or a follow-up someone genuinely forgot about. The doctor’s report arrives, it does not line up, and now the underwriter is verifying rather than assessing. Check your dates against your own records before you sign anything.

Leaving something out to be safe. It surfaces in the report anyway, and an omission discovered by the insurer is far more damaging than the item itself would have been. Disclose everything. It is also what protects the claim later, which is the entire point of the policy.

Common Questions

The questions that come up most often on these files, answered directly.

01

Can you get life insurance with Ehlers-Danlos syndrome in Canada?

Often, yes. Hypermobile Ehlers-Danlos and hypermobility spectrum disorder with no arterial or organ involvement can frequently be placed, and some no-medical applications do not name connective tissue disease among their health questions. Vascular Ehlers-Danlos is assessed far more cautiously, particularly where there has been an arterial event. No Canadian carrier underwriting guide reviewed for this page contains an Ehlers-Danlos entry, so an anonymous preliminary assessment is usually how a meaningful answer gets obtained. Any outcome depends on the complete application and insurer approval.

02

I have hypermobility but no formal diagnosis. Should I wait for one before applying?

Often not, and a no-medical application can be the stronger route in this situation. A fully underwritten application typically includes a broad catch-all question that captures symptoms and unresolved investigations, which can turn an open file into a postponement. A simplified application asks a more defined set of health questions instead. That said, simplified applications also carry eligibility questions, and several ask about tests or investigations that are incomplete or awaiting results, so an open referral can still be reached. You answer every question truthfully on whichever application you complete. The two are simply built differently, and which suits you is worth reviewing before you apply.

03

Can you get life insurance with Marfan syndrome?

It is possible, and a recent aortic root measurement is usually one of the most important parts of the file. One Canadian carrier lists Marfan syndrome at +50 to decline for life insurance, which indicates a well-managed case is not automatically refused in this market. Published guidance on aortic root dilation as a standalone finding indicates a rating where the root is normal in size and a decline where it is dilated, although that guidance addresses a different condition and is not a Marfan grid. A recent echocardiogram with the actual measurements is the document that carries the most weight.

04

Will systemic lupus mean higher premiums?

Often, though the range across Canadian insurers is unusually wide. One major carrier’s published guidance indicates standard to 200% where there is a history of lupus with no active disease. Another indicates possible offers from +50% to +300% one year after diagnosis. A third indicates substandard to decline. Organ involvement, particularly kidney, heart, lung or central nervous system, is where most carriers stop. Because positions diverge this much, comparing carriers matters more on lupus than on most conditions.

05

Do no-medical policies ask about connective tissue disorders?

Some do and some do not, and it varies by carrier rather than by product type. One simplified line works through four steps of health questions covering conditions such as heart failure, stroke with permanent effects, kidney failure on dialysis and recent cancer, and connective tissue disease is not named among that set of medical questions. Other carriers name systemic lupus directly. Those medical questions are not the whole application, however: eligibility questions covering age, residency, coverage amounts, replacement, recent hospitalisation and incomplete tests also apply. Guaranteed acceptance products ask no health questions but carry lower limits and a waiting period on death from natural causes. Full comparison in guaranteed issue and simplified issue explained.

06

My application was postponed. Does that mean I was declined?

No. A postponement means the insurer has paused rather than refused, and it normally names the thing that has to be completed first. The most common trigger is a recommended medical follow-up that has not been done, and frequently that outstanding test has nothing to do with the connective tissue disorder itself. Complete it, resubmit, and the file can reopen. Many postponed applications go on to be approved, although the outcome still depends on what the updated evidence shows.

07

Can my medication affect the application more than my condition does?

It can, and this catches people out. Discoid lupus with no systemic involvement may be considered at standard rates, while the same condition treated with antimalarials, oral steroids, biologics or other immunosuppressants moves to a rating under one carrier’s published guidance. On the no-medical side, at least one application asks about oral corticosteroid use in the past twelve months as its own separate question. Never adjust or stop prescribed treatment because of an insurance application. The right response is to compare carriers, because they do not all ask about medication the same way.

08

Can I get critical illness coverage with a connective tissue disorder?

Sometimes, but it is consistently harder than life insurance and the two are underwritten separately. Published guidance shows cases where life coverage is indicated at a rating while critical illness is declined on the same file. For systemic lupus, one carrier indicates critical illness is unlikely to be considered within four years of diagnosis or where there is current steroid or immunosuppressant use. If both products matter to you, the order in which you apply is worth planning. Our comparison of critical illness insurance companies in Canada covers how definitions differ between carriers.